Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy duo shows promise against rare lung cancer in chinese trial

NCT ID NCT05136677

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. 102 patients who could not have surgery were randomly assigned to receive either the immunotherapy combo or chemotherapy. The main goal was to see if the immunotherapy helped patients live longer. The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

102 people

The number who actually took part.

Started

Jan 2022

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology * Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy) * Available tumor samples for centralized testing * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * Measurable disease Exclusion Criteria: * Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma * Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy * Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy) Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant pleural mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant mesothelioma malignant pleural mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mesothelioma malignant

Contacts and locations

Locations

  • Local Institution - 0001

    Shanghai, Shanghai Municipality, 200030, China

  • Local Institution - 0003

    Changchun, Jilin, 130021, China

  • Local Institution - 0004

    Shenyang, Liaoning, 110042, China

  • Local Institution - 0005

    Changsha, Hunan, 410013, China

  • Local Institution - 0006

    Zhengzhou, Henan, 450003, China

  • Local Institution - 0007

    Tianjin, Tianjin Municipality, 300052, China

  • Local Institution - 0009

    Beijing, Beijing Municipality, 100142, China

  • Local Institution - 0010

    Kunming, Yunnan, 650106, China

  • Local Institution - 0012

    Ningbo, Zhejiang, 315010, China

  • Local Institution - 0013

    Harbin, Heilongjiang, 150081, China

  • Local Institution - 0014

    Hangzhou, Zhejiang, 310003, China

  • Local Institution - 0015

    Yangzhou, Jiangsu, 225001, China

  • Local Institution - 0016

    Ningbo, Zhejiang, 315041, China

  • Local Institution - 0018

    Tianjin, Tianjin Municipality, 300060, China

  • Local Institution - 0020

    Hangzhou, Zhejiang, 310005, China

  • Local Institution - 0021

    Shenyang, Liaoning, 110044, China

  • Local Institution - 0023

    Wuhan, Hunan, 430023, China

  • Local Institution - 0029

    Chengdu, Sichuan, 610041, China

  • Local Institution - 0030

    Qingdao, Shandong, 266003, China

  • Local Institution - 0033

    Taiyuan, Shanxi, 030000, China

  • Local Institution - 0037

    Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.